Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

André Lechel

Showing results (1-10 of 62) with videos related to

Pageof 7
Sort By:
Gut|January 20, 2017
Targeting the correct target in HCCCarmen Berasain, André Lechel
Journal of Hepatology|June 29, 2020
Maternal obesity: A severe risk factor in hepatocarcinogenesis?Sabine Colnot, André Lechel
Gut|March 6, 2016
Early HCC treatment: a future strategy against interferon/miR-484 axis to revert precancerous lesions?André Lechel, Angélique Gougelet
Gastroenterology|March 8, 2008
Rho GTPase and Wnt signaling pathways in hepatocarcinogenesisAndré Lechel, Karl Lenhard Rudolph
Stem Cells International|March 28, 2019
Remodelling and Improvements in Organoid Technology to Study Liver Carcinogenesis in a DishUmesh Tharehalli, Michael Svinarenko, André Lechel
International Journal of Molecular Sciences|April 30, 2021
Iron at the Interface of Hepatocellular CarcinomaRossana Paganoni, André Lechel, Maja Vujic Spasic
The Journal of Pathology|April 11, 2025
Aberrant TERT expression: linking chronic inflammation to hepatocellular carcinoma<sup>†</sup>Rui Dong, Gregoire Najjar, Cagatay Günes, et al.
Journal of Hepatology|September 1, 2004
Telomeres and telomerase: new targets for the treatment of liver cirrhosis and hepatocellular carcinomaAndré Lechel, Michael P Manns, K Lenhard Rudolph
Cancers|July 30, 2020
Telomeres and Telomerase in the Development of Liver CancerLena In der Stroth, Umesh Tharehalli, Cagatay Günes, et al.
Neuroreport|February 15, 2014
Substantial telomere shortening in the substantia nigra of telomerase-deficient mice does not increase susceptibility to MPTP-induced dopamine depletionPatrick Oeckl, Annika Scheffold, André Lechel, et al.
Pageof 7

Showing results (1-10 of 62) with videos related to

Sort By:
Pageof 7
Gut|January 20, 2017
Targeting the correct target in HCCCarmen Berasain, André Lechel
Journal of Hepatology|June 29, 2020
Maternal obesity: A severe risk factor in hepatocarcinogenesis?Sabine Colnot, André Lechel
Gut|March 6, 2016
Early HCC treatment: a future strategy against interferon/miR-484 axis to revert precancerous lesions?André Lechel, Angélique Gougelet
Gastroenterology|March 8, 2008
Rho GTPase and Wnt signaling pathways in hepatocarcinogenesisAndré Lechel, Karl Lenhard Rudolph
Stem Cells International|March 28, 2019
Remodelling and Improvements in Organoid Technology to Study Liver Carcinogenesis in a DishUmesh Tharehalli, Michael Svinarenko, André Lechel
International Journal of Molecular Sciences|April 30, 2021
Iron at the Interface of Hepatocellular CarcinomaRossana Paganoni, André Lechel, Maja Vujic Spasic
The Journal of Pathology|April 11, 2025
Aberrant TERT expression: linking chronic inflammation to hepatocellular carcinoma<sup>†</sup>Rui Dong, Gregoire Najjar, Cagatay Günes, et al.
Journal of Hepatology|September 1, 2004
Telomeres and telomerase: new targets for the treatment of liver cirrhosis and hepatocellular carcinomaAndré Lechel, Michael P Manns, K Lenhard Rudolph
Cancers|July 30, 2020
Telomeres and Telomerase in the Development of Liver CancerLena In der Stroth, Umesh Tharehalli, Cagatay Günes, et al.
Neuroreport|February 15, 2014
Substantial telomere shortening in the substantia nigra of telomerase-deficient mice does not increase susceptibility to MPTP-induced dopamine depletionPatrick Oeckl, Annika Scheffold, André Lechel, et al.
Pageof 7